Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Brain Metastases: Diagnosis and Treatment
share announcement

Brain Metastases: Diagnosis and Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: 15 August 2024 | Viewed by 589

Special Issue Editor

Dr. Alla Gabriella Wernicke

E-Mail Website
Guest Editor
Department of Radiation Medicine, Lenox Hill Hospital, New York, NY, USA
Interests: brain metastases; breast cancer; brachytherapy

Special Issue Information

Dear Colleagues,

Brain metastases represent one of the most formidable challenges in oncology, signaling advanced disease and necessitating a multidisciplinary approach to their treatment and care. The "Brain Metastases: Diagnosis and Treatment" Special Issue aims to bring together original research, clinical studies, and comprehensive reviews that delve into the complexities of detecting and managing brain metastases.

We invite submissions that explore novel diagnostic techniques or quandaries, evaluate the efficacy of emerging therapies, and provide insights into the mechanisms underpinning metastatic brain tumors. This Special Issue seeks to serve as a nexus of ideas from a broad spectrum of the medical and scientific communities.

Contributions may range from advancements in imaging and biomarker discovery to treatment modalities such as targeted therapy, immunotherapy, and surgical interventions. We also encourage discussions on patient quality of life, symptom management, and long-term outcomes. Through this scholarly exchange, we aspire to pave the way for innovations that will significantly improve patient prognosis and treatment experiences.

Dr. Alla Gabriella Wernicke
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain metastases
  • neuro-oncology
  • brain neoplasms
  • neurosurgery
  • diagnostic imaging
  • biomarkers
  • targeted therapy
  • immunotherapy
  • radiotherapy
  • quality of life

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 1554 KiB  
Article
A Phase II Trial of Bevacizumab in Patients with Recurrent/Progressive Solid Tumor Brain Metastases That Have Progressed Following Whole-Brain Radiation Therapy
by Karan Dixit, Lauren Singer, Sean Aaron Grimm, Rimas V. Lukas, Margaret A. Schwartz, Alfred Rademaker, Hui Zhang, Masha Kocherginsky, Sofia Chernet, Laura Sharp, Valerie Nelson, Jeffrey J. Raizer and Priya Kumthekar
Cancers 2024, 16(11), 2133; https://doi.org/10.3390/cancers16112133 - 4 Jun 2024
Viewed by 398
Abstract
Patients with solid tumor brain metastases that progress after whole-brain radiation have limited options. This prospective trial investigated the efficacy, safety, and tolerability of bevacizumab as salvage therapy in this population. Eligible patients received bevacizumab 10 mg/kg intravenously every 2 weeks until progression. [...] Read more.
Patients with solid tumor brain metastases that progress after whole-brain radiation have limited options. This prospective trial investigated the efficacy, safety, and tolerability of bevacizumab as salvage therapy in this population. Eligible patients received bevacizumab 10 mg/kg intravenously every 2 weeks until progression. The primary endpoint was radiologic response using Response Assessment in Neuro-Oncology (RANO) criteria. The secondary endpoints were progression-free survival (PFS), overall survival (OS), duration of response, and safety. Quality of life (QOL) was studied using the Functional Assessment of Cancer Therapy-Brain (FACT-Br) scale. Twenty-seven patients were enrolled, with twenty-four having evaluable data for response. The majority of histologies (n = 21, 78%) were breast cancer. The remaining histologies were non-small-cell lung cancer (n = 4, 15%), neuroendocrine cancer (n = 1, 3%), and papillary fallopian serous adenocarcinoma (n = 1, 3%). Eighteen patients had radiologic response, with two patients demonstrating partial response (8.33%) and sixteen patients demonstrating stable disease (66.7%). The median duration of response was 203 days. PFS at 6 months was 46%, median PFS was 5.3 m, and median OS was 9.5 m. Treatment was well tolerated, with six patients experiencing grade 3 lymphopenia and hypertension. There was one grade 3 thromboembolism. QOL was not negatively impacted. Bevacizumab is a safe and feasible salvage treatment with durable response and favorable overall survival for patients with progressive brain metastases after whole-brain radiation. Full article
(This article belongs to the Special Issue Brain Metastases: Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop